A pilot study of neoadjuvant biweekly doxorubicin and cyclophosphamide (AC) with GMCSF [granulocyte-macrophage colony-stimulating factors] followed by weekly carboplatin/paclitaxel with plus and minus traztuzumab [trastuzumab] (TC +/- H) in the treatment of breast cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Carboplatin; Cyclophosphamide; Doxorubicin; Paclitaxel; Trastuzumab
- Indications Breast cancer
- Focus Therapeutic Use
- 02 Mar 2018 Biomarkers information updated
- 17 Jan 2008 The expected completion date for this trial is now 1 Dec 2008 as reported by ClinicalTrials.gov.
- 23 Oct 2006 New trial record.